Corporate balance sheets are littered with failed acquisitions, but one company's experiment in buying up smaller competitors is producing great results.
News & Analysis: Thermo Fisher Scientific
Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.
Will Thermo Fisher be able to complete its deal to acquire Qiagen, or will shareholders vote it down?
These companies are all doing well amid the coronavirus pandemic.
TMO earnings call for the period ending June 27, 2020.
The company got a lot of help from COVID-19.
When the economy struggles, these two pharma companies take it in stride because they know the rest of the industry depends on them for critical products.
These three companies have the resources and the positioning to survive the harshest of economic conditions.
Here's why the winning streak on this life science solutions stock is far from over.
Both companies have moved aggressively to produce diagnostic tests for COVID-19, and both are positioned for growth.